Adherium (ASX:ADR) develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.
Adherium is a global leader in digital health technologies which address sub-optimal medication use in chronic disease.
Its Hailie™ solution (previously known as the Smartinhaler™ platform) has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease.
Adherium has the broadest range of connected devices for respiratory medications globally. Adherium’s Hailie™ sensors attach to prescription inhalers to provide reminders and to monitor inhaler usage.
The Hailie™ portal (previously known as SmartinhalerLive) uses wireless communications technology to provide real time data collection and reporting from the Company’s Hailie sensors.
Adherium operates globally from bases in New Zealand, Australia, USA and UK.